Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 in Relapsed or Refractory Leukemia, Mantle Cell Lymphoma, or Myelofibrosis
NCT00081874Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2004
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in leukemia, mantle cell lymphoma (MCL) and myelofibrosis (MF), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Apr 2004; status: completed.
02
Drugs
everolimus
03
Conditions
leukemiamantle cell lymphoma (MCL)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT00081874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081874.